719 Stock Overview Through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical raw materials in the People's Republic of China, the Americas, Europe, and internationally. More details
Rewards Risk Analysis No risks detected for 719 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Shandong Xinhua Pharmaceutical Company Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Shandong Xinhua Pharmaceutical Historical stock prices Current Share Price HK$5.83 52 Week High HK$8.05 52 Week Low HK$4.80 Beta -0.019 1 Month Change -1.69% 3 Month Change 10.00% 1 Year Change 4.48% 3 Year Change 23.78% 5 Year Change 55.47% Change since IPO 186.00%
Recent News & Updates
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) signed an equity acquisition intention agreement to acquire 75% stake in Novosana (Taicang) Bio Feed Co., Ltd. from Novosana (Europe) B.V. Dec 12
Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation Nov 05
Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023) Oct 30
Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application Oct 28
Investor sentiment improves as stock rises 16% Oct 02
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Sep 30 See more updates
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) signed an equity acquisition intention agreement to acquire 75% stake in Novosana (Taicang) Bio Feed Co., Ltd. from Novosana (Europe) B.V. Dec 12
Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation Nov 05
Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023) Oct 30
Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application Oct 28
Investor sentiment improves as stock rises 16% Oct 02
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024 Sep 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application Sep 13
Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs Sep 02
Upcoming dividend of HK$0.027 per share Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2023) Aug 23
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024 Aug 22
Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024 Jul 24
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024 Jun 29
Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year Jun 28
Dividend of HK$0.27 announced Jun 28
Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024 Jun 26
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024 May 29
First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023) Apr 26
Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024 Mar 30
Full year 2023 earnings released: EPS: CN¥0.74 (vs CN¥0.62 in FY 2022) Mar 29
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023 Mar 28
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient Feb 28
Now 21% overvalued Jan 25
Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price Jan 23
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate Jan 19
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024 Dec 30
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes Dec 26
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg) Dec 15
Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2022) Oct 29
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat Oct 11
Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 2Q 2022) Aug 25
Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration Aug 12
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee Jul 27
Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023 Jul 22 Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation Jul 15
Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation Jul 11
Upcoming dividend of HK$0.22 per share at 3.6% yield Jun 30
Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs Jun 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration Jun 14
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 25
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 24
Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.56 in FY 2021) Mar 27
Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt Mar 07
Investor sentiment improves as stock rises 24% Feb 17
Investor sentiment deteriorated over the past week Dec 27
Investor sentiment improved over the past week Dec 05
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt? Nov 18
Less than half of directors are independent Nov 16
Investor sentiment improved over the past week Nov 08
Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2021) Oct 26
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022 Oct 13
Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes Sep 20
Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 2Q 2021) Aug 31
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022 Aug 19
Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022 Jul 30
These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively Jul 27
Investor sentiment deteriorated over the past week Jul 21
Upcoming dividend of HK$0.18 per share Jul 08
Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18 Jul 04
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager Jul 04
Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022 Jul 01
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022 Jun 01
Investor sentiment improved over the past week May 27
Investor sentiment improved over the past week Apr 29
Less than half of directors are independent Apr 27
Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021 Apr 01
Full year 2021 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in FY 2020) Mar 31
Now 21% undervalued after recent price drop Mar 15
Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Mar 09
We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt Dec 21
Investor sentiment improved over the past week Dec 21
Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 3Q 2020) Oct 16
Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.14 in 2Q 2020) Aug 30
Shandong Xinhua Pharmaceutical Company Limited announced that it expects to receive CNY 249.999998 million in funding from Hualu Investment Development Co., Ltd. Apr 16
Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist? Apr 06
Full year 2020 earnings released: EPS CN¥0.52 (vs CN¥0.48 in FY 2019) Apr 01
What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)? Mar 19
Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment? Feb 26
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021 Feb 24
New 90-day high: HK$5.40 Feb 17
Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability? Feb 05
Investor sentiment improved over the past week Feb 03
New 90-day high: HK$3.88 Jan 20
Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years Jan 18
Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors? Dec 29
Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments Dec 23
New 90-day low: HK$3.64 Dec 15
Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares? Dec 14
Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments Dec 02
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt? Nov 26
Shandong Xinhua Pharmaceutical Company Limited Announces the Retirement of Certain Directors and Supervisors Nov 20
Third quarter earnings released Oct 23
Shandong Xinhua Pharmaceutical Company Limited to Report Nine Months, 2020 Results on Oct 22, 2020 Oct 13
New 90-day low: HK$3.86 Sep 24
New 90-day low - HK$3.97 Sep 08 Shareholder Returns 719 HK Pharmaceuticals HK Market 7D 0.7% -1.9% -0.5% 1Y 4.5% -3.9% 19.9%
See full shareholder returns
Return vs Market: 719 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility Is 719's price volatile compared to industry and market? 719 volatility 719 Average Weekly Movement 9.4% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stable Share Price: 719 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 719's weekly volatility (9%) has been stable over the past year.
About the Company Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical raw materials in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic drugs; cardiovascular and cerebrovascular drugs; anti-infective drugs and central nervous system, neurological drugs; and other drugs. It engages in the development of real estate business.
Show more Shandong Xinhua Pharmaceutical Company Limited Fundamentals Summary How do Shandong Xinhua Pharmaceutical's earnings and revenue compare to its market cap? 719 fundamental statistics Market cap HK$9.65b Earnings (TTM ) HK$478.11m Revenue (TTM ) HK$8.89b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 719 income statement (TTM ) Revenue CN¥8.34b Cost of Revenue CN¥6.32b Gross Profit CN¥2.01b Other Expenses CN¥1.56b Earnings CN¥448.62m
Dividends
0.9% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 23:27 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shandong Xinhua Pharmaceutical Company Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alex Fan GF Securities (Hong Kong) Brokerage Limited Ming Li Industrial Securities Co. Ltd. Guohe Fan Phillip Securities (HK)
Show 0 more analysts 
